Utilizing aromatase inhibitors compared with tamoxifen reduce recurrence in estrogen receptor-positive breast cancer in patients who were menopausal and received ovarian suppression.
Black patients may have poorer outcomes during breast cancer treatment than White patients.
FoundationOne CDx has been approved by the FDA as a companion diagnostic for patients with melanoma undergoing treatment with a BRAF inhibitor.
Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.
Research presented at the 2021 San Antonio Breast Cancer Symposium highlighted survival improvements for postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer when treated with ribociclib plus letrozole over placebo.
Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.
Pooled efficacy and safety data confirm that patients who self-identify as Black or Hispanic can be safely treated with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.
Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.
Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.
Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.